Download PDF
Semin Liver Dis 2008; 28(2): 175-187
DOI: 10.1055/s-2008-1073117
© Thieme Medical Publishers

Acute Liver Failure Due to Drugs

Robert J. Fontana1
  • 1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan
Further Information

Publication History

Publication Date:
02 May 2008 (online)

    Permissions and Reprints

ABSTRACT

Acetaminophen overdose and idiosyncratic drug-induced liver injury (DILI) are the most commonly identified causes of acute liver failure (ALF) in the United States. Suspected acetaminophen hepatotoxicity can be effectively treated with N-acetylcysteine but still an estimated 500 patients die each year. Product labeling changes, dispensing restrictions, and reformulation of acetaminophen containing narcotic analgesics have been proposed to reduce the rising incidence of this preventable form of dose-dependent liver injury. In contrast, idiosyncratic DILI is not preventable due to our lack of understanding of host susceptibility and outcome factors. Patients with ALF due to DILI are difficult to diagnose and have a low likelihood of spontaneous recovery. Patients with severe idiosyncratic DILI should be urgently referred to a transplant center as there are no established medical treatments beyond drug discontinuation. Investigation of host variability in metabolic, regeneration, and immunological pathways may provide insights into the molecular basis of DILI as well as improved diagnostic and prognostic biomarkers.

KEYWORDS

Hepatotoxicity - acute liver failure - idiosyncratic - causality assessment

REFERENCES

  • 1 Centers for Disease Control and Prevention . Nonfatal, unintentional medication exposures among young children: United States 2001-2003.  MMWR Morb Mortal Wkly Rep. 2006;  55(RR-16) 1-5
    PubMedGoogle Scholar
  • 2 Lazarou J, Pomeranz B H, Corey P N. Incidence of adverse drug reactions in hospitalized patients: an analysis of prospective studies.  JAMA. 1998;  279 1200-1205
    Google Scholar
  • 3 Lee W M, Senior J R. Recognizing drug-induced liver injury: current problems, possible solutions.  Toxicol Pathol. 2005;  33 155-164
    CrossrefPubMedGoogle Scholar
  • 4 Navarro V J, Senior J R. Drug-related hepatotoxicity.  N Engl J Med. 2006;  354 731-739
    CrossrefPubMedGoogle Scholar
  • 5 Ostapowicz G, Fontana R J, Schiødt F V et al.. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.  Ann Intern Med. 2002;  137 947-954
    CrossrefPubMedGoogle Scholar
  • 6 Watkins P B. Idiosyncratic liver injury: challenges and approaches.  Toxicol Pathol. 2005;  33 1-5
    PubMedGoogle Scholar
  • 7 Meier Y, Cavallaro M, Roos M et al.. Incidence of drug-induced liver injury in medical inpatients.  Eur J Clin Pharmacol. 2005;  61 135-143
    CrossrefPubMedGoogle Scholar
  • 8 Duh M S, Walker A M, Kronlund Jr K H. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts.  Pharmacoepidemiol Drug Saf. 1999;  8 275-283
    CrossrefPubMedGoogle Scholar
  • 9 Beard K, Belic L, Aselton P et al.. Outpatient drug-induced parenchymal liver disease requiring hospitalization.  J Clin Pharmacol. 1986;  26 633-637
    PubMedGoogle Scholar
  • 10 Galan M V, Potts J A, Silverman A L, Gordon S C. The burden of acute non-fulminant drug-induced hepatitis in a United States tertiary referral center.  J Clin Gastroenterol. 2005;  39 64-67
    PubMedGoogle Scholar
  • 11 Vuppalanchi R, Liangpunsakul S, Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic jaundice in the United States?.  Am J Gastroenterol. 2007;  102 558-562
    CrossrefPubMedGoogle Scholar
  • 12 De Valle M B, Klinteberg A V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital outpatient hepatology clinic.  Aliment Pharmacol Ther. 2006;  24 1187-1195
    CrossrefPubMedGoogle Scholar
  • 13 Sgro C, Clinard F, Ouazier K et al.. Incidence of drug-induced hepatic injuries: a French population-based study.  Hepatology. 2002;  36 451-455
    CrossrefPubMedGoogle Scholar
  • 14 Verma A, Lilienfeld D E. The need for a population-based surveillance system for liver disease in the United States.  Pharmacoepidemiol Drug Saf. 2004;  13 821-824
    CrossrefPubMedGoogle Scholar
  • 15 Hoofnagle J H. Drug-Induced Liver Injury Network (DILIN).  Hepatology. 2004;  40 773
    PubMedGoogle Scholar
  • 16 Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity.  Hepatology. 2001;  33 308-310
    CrossrefPubMedGoogle Scholar
  • 17 Andrade R J, Lucena M I, Fernandez M C et al.. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.  Gastroenterology. 2005;  129 512-521
    CrossrefPubMedGoogle Scholar
  • 18 Ibanez L, Perez E, Vidal X, Laporte J R. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic disease: epidemiological and clinical features, and exposure to drugs.  J Hepatol. 2002;  37 592-600
    CrossrefPubMedGoogle Scholar
  • 19 Sharp J R, Ishak K G, Zimmerman H J. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin.  Ann Intern Med. 1980;  92 14-19
    CrossrefPubMedGoogle Scholar
  • 20 Lucena M I, Andrade R J, Fernandez M C et al.. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain.  Hepatology. 2006;  44 850-856
    CrossrefPubMedGoogle Scholar
  • 21 Lucena M I, Camargo R, Andrade R J, Perez-Sanchez C F, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity.  Hepatology. 2001;  33 123-130
    CrossrefPubMedGoogle Scholar
  • 22 Graham D J. Telithromycin and acute liver failure.  N Engl J Med. 2006;  355 2260-2261
    CrossrefPubMedGoogle Scholar
  • 23 Gitlin N, Neil J L, Spurr C L et al.. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.  Ann Intern Med. 1998;  129 36-38
    CrossrefPubMedGoogle Scholar
  • 24 Kohlroser J, Mathai J, Reichheld J, Banner B F, Bonkovsky H L. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.  Am J Gastroenterol. 2000;  95 272-276
    CrossrefPubMedGoogle Scholar
  • 25 Molinari M, Watt K DS, Kruszyna T et al.. Acute liver failure induced by green tea extracts: case report and review of the literature.  Liver Transpl. 2006;  12 1892-1895
    CrossrefPubMedGoogle Scholar
  • 26 Wai C T, Tan B H, Chan C L et al.. Drug-induced liver injury at an Asian center: a prospective study.  Liver Int. 2007;  27 465-474
    CrossrefPubMedGoogle Scholar
  • 27 Shapiro M A, Lewis J H. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls.  Clin Liver Dis. 2007;  11 477-505
    CrossrefPubMedGoogle Scholar
  • 28 Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.  J Clin Epidemiol. 1993;  46 1323-1330
    CrossrefPubMedGoogle Scholar
  • 29 Rockey D C, Seeff L B, Freston J W et al.. Comparison between expert opinion and RUCAM for assignment of causality in drug-induced liver injury [abstract].  Gastroenterology. 2007;  132 M1777
    PubMedGoogle Scholar
  • 30 Leeder J S, Xu X, Timsit Y, Gaedigk A. Non-monooxygenase cytochromes P450 as potential human autoantigens in anticonvulsant hypersensitivity reactions.  Pharmacogenetics. 1998;  8 211-225
    PubMedGoogle Scholar
  • 31 Aithal G P, Ramsay L, Daly A K et al.. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity.  Hepatology. 2004;  39 1430-1440
    CrossrefPubMedGoogle Scholar
  • 32 Sullivan J R, Shear N H. The drug hypersensitivity syndrome: what is the pathogenesis?.  Arch Dermatol. 2001;  137 357-364
    PubMedGoogle Scholar
  • 33 Neuman M G, Shear N H, Malkiewicz I M et al.. Immunopathogenesis of hypersensitivity syndrome reactions to sulfonamides.  Transl Res. 2007;  149 243-253
    PubMedGoogle Scholar
  • 34 Takikawa H, Takamori Y, Kumagi T et al.. Assessment of 287 Japanese cases of drug-induced liver injury by the diagnostic scale of the International Consensus Meeting.  Hepatol Res. 2003;  27 192-195
    CrossrefPubMedGoogle Scholar
  • 35 Davern T J, James L P, Hinson J A et al.. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure.  Gastroenterology. 2006;  130 687-694
    CrossrefPubMedGoogle Scholar
  • 36 James L P, Mayeux P R, Hinson J A. Acetaminophen-induced hepatotoxicity.  Drug Metab Dispos. 2003;  31 1499-1506
    CrossrefPubMedGoogle Scholar
  • 37 Watkins P B, Seeff L B. Drug-induced liver injury: summary of a single-topic clinical research conference.  Hepatology. 2006;  43 618-631
    CrossrefPubMedGoogle Scholar
  • 38 Wilke R A, Lin D W, Roden D M et al.. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.  Nat Rev Drug Discov. 2007;  6 904-916
    CrossrefPubMedGoogle Scholar
  • 39 O'Donohue J, Oien K A, Donaldson P et al.. Co-amoxiclav jaundice: clinical and histological features and HLA class II association.  Gut. 2000;  47 717-720
    CrossrefPubMedGoogle Scholar
  • 40 Andrade R J, Lucena I, Alonso A et al.. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease.  Hepatology. 2004;  39 1603-1612
    CrossrefPubMedGoogle Scholar
  • 41 Pachkoria K, Lucena M I, Ruiz-Cabello F et al.. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).  Br J Pharmacol. 2007;  150 808-815
    CrossrefPubMedGoogle Scholar
  • 42 Liu C, Aronow B J, Jeffa A G et al.. Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis.  Gastroenterology. 2007;  132 119-126
    CrossrefPubMedGoogle Scholar
  • 43 Pauli-Magnus C, Meier P J. Hepatobiliary transporters and drug-induced cholestasis.  Hepatology. 2006;  44 778-787
    CrossrefPubMedGoogle Scholar
  • 44 Watanabe I, Tomita A, Shimizu M et al.. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus.  Clin Pharmacol Ther. 2003;  73 435-455
    CrossrefPubMedGoogle Scholar
  • 45 Kleiner D A, Chalasani N P, Conjeevaram H S et al.. Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH Drug-Induced Liver Injury Network (DILIN) study [abstract].  Gastroenterology. 2007;  137 M1775
    PubMedGoogle Scholar
  • 46 Bjornsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury.  Aliment Pharmacol Ther. 2007;  25 1411-1421
    CrossrefPubMedGoogle Scholar
  • 47 Donaldson B W, Gopinath R, Wanless I R et al.. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators.  Hepatology. 1993;  18 1370-1376
    CrossrefPubMedGoogle Scholar
  • 48 Hanau C, Munoz S J, Rubin R. Histopathological heterogeneity in fulminant hepatic failure.  Hepatology. 1995;  21 345-351
    CrossrefPubMedGoogle Scholar
  • 49 Stravitz R T, Kramer A H, Davern T et al.. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group.  Crit Care Med. 2007;  35 2498-2508
    CrossrefPubMedGoogle Scholar
  • 50 Trey C, Davidson C S. The management of fulminant hepatic failure.  Prog Liver Dis. 1970;  3 282-298
    PubMedGoogle Scholar
  • 51 Hoofnagle J H, Carithers R L, Shapiro C et al.. Fulminant hepatic failure: summary of a workshop.  Hepatology. 1995;  21 240-253
    CrossrefPubMedGoogle Scholar
  • 52 Dalton H R, Fellows H J, Stableforth W et al.. The role of hepatitis E virus testing in drug-induced liver injury.  Aliment Pharmacol Ther. 2007;  26 1429-1435
    CrossrefPubMedGoogle Scholar
  • 53 Teo E K, Ostapowicz G, Hussain M et al.. Hepatitis B infection in patients with acute liver failure in the United States.  Hepatology. 2001;  33 972-976
    CrossrefPubMedGoogle Scholar
  • 54 Levitsky J, Thadareddy A, Lakeman F D et al.. Quantitative measurement of herpes simplex virus before and after liver transplantation.  , [abstract] Am J Transplant. 2007;  7(suppl 2) 1388
    PubMedGoogle Scholar
  • 55 Lee W M, Brown K E, Young N S et al.. Brief report: no evidence of parvovirus B19 or hepatitis E virus as causes of acute liver failure.  Dig Dis Sci. 2006;  51 1712-1715
    CrossrefPubMedGoogle Scholar
  • 56 Umemura T, Tanaka E, Ostapowicz G et al.. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis.  J Infect Dis. 2003;  188 1545-1552
    CrossrefPubMedGoogle Scholar
  • 57 Russo M W, Galanko J A, Shrestha R et al.. Liver transplantation for acute liver failure from drug-induced liver injury in the United States.  Liver Transpl. 2004;  10 1018-1023
    CrossrefPubMedGoogle Scholar
  • 58 Wong W M, Wu P C, Yuen M F et al.. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection.  Hepatology. 2000;  31 201-206
    CrossrefPubMedGoogle Scholar
  • 59 Mok M Y, Ng W L, Yuen M F et al.. Safety of disease-modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.  Clin Exp Rheumatol. 2000;  18 363-368
    PubMedGoogle Scholar
  • 60 Zachariae H. Liver biopsies and methotrexate: a time for reconsideration?.  J Am Acad Dermatol. 2000;  42 531-534
    CrossrefPubMedGoogle Scholar
  • 61 Rutherford A, Davern T, Hay J E et al.. Influence of high body mass index on outcome in acute liver failure.  Clin Gastroenterol Hepatol. 2006;  4 1544-1549
    CrossrefPubMedGoogle Scholar
  • 62 Lammert C, Bjornsson E, Saha C et al.. Relationship between medication dose and idiosyncratic drug-induced liver injury.  Hepatology. 2007;  46(suppl 1) A1288
    PubMedGoogle Scholar
  • 63 Squires R H, Shneider B L, Bucuvalas J et al.. Acute liver failure in children: the first 348 patients in the Pediatric Acute Liver Failure Study Group.  J Pediatr. 2006;  148 652-658
    CrossrefPubMedGoogle Scholar
  • 64 Lewis J H. “Hy's Law,” the “Rezulin Rule,” and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective.  Pharmacoepidemiol Drug Saf. 2006;  15 221-229
    CrossrefPubMedGoogle Scholar
  • 65 Zimmerman H J. Hepatoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia, PA; Lippincott Williams & Wilkins 1999
    Google Scholar
  • 66 Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease.  Hepatology. 2005;  42 481-489
    CrossrefPubMedGoogle Scholar
  • 67 Ohmori S, Shiraki K, Inoue H et al.. Clinical characteristics and prognostic indicators of drug-induced fulminant hepatic failure.  Hepatogastroenterology. 2003;  50 1531-1534
    PubMedGoogle Scholar
  • 68 Food and Drug Administration . Guidance for industry: drug-induced liver injury: premarketing clinical evaluation.  Fed Regist. 2007;  , October 24
    PubMedGoogle Scholar
  • 69 O'Grady J G, Alexander G JM, Hayllar K M et al.. Early indicators of prognosis in fulminant hepatic failure.  Gastroenterology. 1989;  97 439-455
    PubMedGoogle Scholar
  • 70 Pauwels A, Mostefa-Kara N, Florent C et al.. Emergency liver transplantation for acute liver failure: evaluation of London and Clichy criteria.  J Hepatol. 1993;  17 124-127
    CrossrefPubMedGoogle Scholar
  • 71 Bernal W, Donaldson N, Wyncoll D et al.. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study.  Lancet. 2002;  359 558-563
    CrossrefPubMedGoogle Scholar
  • 72 Larson A M, Polson J, Fontana R J et al.. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study.  Hepatology. 2005;  42 1364-1372
    CrossrefPubMedGoogle Scholar
  • 73 Schmidt L E, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury.  Hepatology. 2005;  41 26-31
    CrossrefPubMedGoogle Scholar
  • 74 Schmidt L E, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity.  Hepatology. 2002;  36 659-665
    CrossrefPubMedGoogle Scholar
  • 75 Makin A J, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993).  Gastroenterology. 1995;  109 1907-1916
    CrossrefPubMedGoogle Scholar
  • 76 Constantine J K, Wendon J, Safinia N et al.. Long-term outcomes for patients transplanted for acetaminophen-induced acute liver failure: no worse than for other etiologies.  , [abstract] Hepatology. 2007;  46 575
    PubMedGoogle Scholar
  • 77 Davies M H, Harrison R F, Elias E, Hubscher S G. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis.  J Hepatol. 1994;  20 112-116
    CrossrefPubMedGoogle Scholar
  • 78 Levy C, Linder K D. Drug-induced cholestasis.  Clin Liver Dis. 2003;  7 311-330
    CrossrefPubMedGoogle Scholar
  • 79 Aithal P G, Day C P. The natural history of histologically proved drug-induced liver disease.  Gut. 1999;  44 731-735
    CrossrefPubMedGoogle Scholar
  • 80 Andrade R J, Lucena M I, Kaplowitz N et al.. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry.  Hepatology. 2006;  44 1581-1588
    CrossrefPubMedGoogle Scholar
  • 81 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting.  J Hepatol. 1990;  11 272-276
    PubMedGoogle Scholar
  • 82 Bjornsson E, Kalaitzakis E, Av Klintberg V, Alem N, Olsson R. Long-term follow-up of patients with mild to moderate drug-induced liver injury.  Aliment Pharmacol Ther. 2007;  26 79-85
    CrossrefPubMedGoogle Scholar
  • 83 Sterling R K, Luketic V A, Sanyal A J et al.. Treatment of fulminant hepatic failure with intravenous prostaglandin E1.  Liver Transpl Surg. 1998;  4 424-431
    CrossrefPubMedGoogle Scholar
  • 84 O'Grady J G, Gimson A E, O'Brien C J et al.. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure.  Gastroenterology. 1988;  94 1186-1192
    PubMedGoogle Scholar
  • 85 Demetriou A A, Brown R S, Busuttil R W et al.. Prospective, randomized, multicenter controlled trial of a bioartificial liver in treating acute liver failure.  Ann Surg. 2004;  239 660-667
    CrossrefPubMedGoogle Scholar
  • 86 Pohle T, Menzel J, Domschke W. Minocycline and fulminant hepatic failure necessitating liver transplantation.  Am J Gastroenterol. 2000;  95 560-561
    PubMedGoogle Scholar
  • 87 Furhoff A K. Adverse reactions with methyldopa: a decade's reports.  Acta Med Scand. 1978;  203 425-428
    PubMedGoogle Scholar
  • 88 Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline-induced autoimmune hepatitis and systemic lupus erythematous-like syndrome.  BMJ. 1996;  312 169-172
    CrossrefPubMedGoogle Scholar
  • 89 Dechene A, Treicherl U, Gerken G et al.. Effectiveness of a steroid and ursodeoxycholic acid combination therapy with drug-induced subacute liver failure.  Hepatology. 2005;  42 A358
    PubMedGoogle Scholar
  • 90 Rakela J, Mosley J W, Edwards V M et al.. A double-blinded randomized trial of hydrocortisone in acute hepatic failure.  Dig Dis Sci. 1991;  36 1223-1228
    CrossrefPubMedGoogle Scholar
  • 91 European Association for the Study of the Liver Group . Randomized trial of steroid therapy in acute liver failure.  Gut. 1979;  20 620-623
    CrossrefPubMedGoogle Scholar
  • 92 Walsh T S, Hopton P, Philips B J et al.. The effect of n-acetylcysteine on oxygen transport and uptake in patients with fulminant hepatic failure.  Hepatology. 1998;  27 1332-1340
    CrossrefPubMedGoogle Scholar
  • 93 Sklar G E, Subramaniam M. Acetylcysteine treatment for non-acetaminophen-induced acute liver failure.  Ann Pharmacother. 2004;  38 498-501
    CrossrefPubMedGoogle Scholar
  • 94 Lee W M, Rossaro L, Fontana R J et al.. Intravenous n-acetylcysteine improves spontaneous survival in early stage non-acetaminophen acute liver failure.  , [abstract] Hepatology. 2007;  46 A79
    PubMedGoogle Scholar
  • 95 Legras A, Bergemer-Fouquet A M, Jonville-Bera A P. Fatal hepatitis with leflunomide and itraconazole.  Am J Med. 2002;  113 352-353
    CrossrefPubMedGoogle Scholar
  • 96 Van Roon E N, Jansen T L, Houtman N M et al.. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity.  Drug Saf. 2004;  27 345-352
    CrossrefPubMedGoogle Scholar
  • 97 Boyer J L. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease?.  Gastroenterology. 2005;  129 735-740
    CrossrefPubMedGoogle Scholar
  • 98 Zimmerman H J, Maddrey W C. Acetaminophen hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure.  Hepatology. 1995;  22 767-773
    CrossrefPubMedGoogle Scholar
  • 99 Whitcomb D C, Block G D. Association of acetaminophen hepatotoxicity with fasting and ethanol use.  JAMA. 1994;  272 1845-1850
    CrossrefPubMedGoogle Scholar
  • 100 Schmidt L E, Kalhoff K, Poulsen H E. Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity.  Hepatology. 2002;  35 876-882
    CrossrefPubMedGoogle Scholar
  • 101 Slattery J T, Nelson S D, Thummel K E. The complex interaction between ethanol and acetaminophen.  Clin Pharmacol Ther. 1996;  60 241-246
    CrossrefPubMedGoogle Scholar
  • 102 Litovitz T L, Klein-Schwartz W, White S et al.. 2000 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.  Am J Emerg Med. 2001;  19 337-395
    CrossrefPubMedGoogle Scholar
  • 103 Bond G R, Hite L K. Population-based incidence and outcome of acetaminophen poisoning by type of ingestion.  Acad Emerg Med. 1999;  6 1115-1120
    PubMedGoogle Scholar
  • 104 Nourjah P, Ahmad S R, Karwoski C, Willy M. Estimates of acetaminophen-associated overdoses in the United States.  Pharmacoepidemiol Drug Saf. 2006;  15 398-405
    CrossrefPubMedGoogle Scholar
  • 105 Rowden A K, Norvell J, Eldridge D L, Kirk M A. Updates on acetaminophen toxicity.  Med Clin North Am. 2005;  89 1145-1159
    CrossrefPubMedGoogle Scholar
  • 106 Schiødt F V, Rochling F A, Casey D L et al.. Acetaminophen toxicity in an urban county hospital.  N Engl J Med. 1997;  337 1112-1117
    CrossrefPubMedGoogle Scholar
  • 107 Lee W M. Acetaminophen toxicity: changing perceptions on a social/medical issue.  Hepatology. 2007;  46 966-970
    CrossrefPubMedGoogle Scholar
  • 108 Rumack B H. Acetaminophen hepatotoxicity: the first 35 years.  J Toxicol Clin Toxicol. 2002;  40 3-20
    PubMedGoogle Scholar
  • 109 Myers R P, Li B, Fong A, Shaheen A A, Quan H. Hospitalizations for acetaminophen overdose: a Canadian population-based study from 1995-2004.  BMC Public Health. 2007;  7 143-151
    CrossrefPubMedGoogle Scholar
  • 110 Fontana R J, Adams P C. “Unintentional” acetaminophen overdose on the rise: who is responsible?.  Can J Gastroenterol. 2006;  20 319-324
    PubMedGoogle Scholar
  • 111 Kaplowitz N. Acetaminophen hepatotoxicity: what do we know, what don't we know, and what do we do next?.  Hepatology. 2004;  40 23-26
    CrossrefPubMedGoogle Scholar
  • 112 Prince M I, Thomas S H, James O F, Hudson M. Reduction in incidence of severe paracetamol poisoning.  Lancet. 2000;  355 2047-2048
    CrossrefPubMedGoogle Scholar
  • 113 Hawton K, Simkin S, Deeks J et al.. UK legislation on analgesic packs: before and after study of long-term effect on poisonings.  BMJ. 2004;  329 1076
    CrossrefPubMedGoogle Scholar
  • 114 Food and Drug Administration .21 CRF Parts 201 and 343. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use: proposed amendment of the tentative final monograph, Required warnings and other labeling. Federal Register Parts 201 and 343 (12/26/06) Available at: http://www.accessdata.fda.gov/scripts/oc/ohrms/frbydocket.cfm
  • 115 Osborne Z P, Bryant S M. Patients discharged with a prescription for acetaminophen-containing narcotic analgesics do not receive appropriate written instructions.  Am J Emerg Med. 2003;  21 48-50
    CrossrefPubMedGoogle Scholar

Robert J FontanaM.D. 

Associate Professor of Medicine, Department of Internal Medicine, University of Michigan Medical Center

3912 Taubman Center, Ann Arbor, MI 48109-0362

Email: rfontana@med.umich.edu

      >